Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Ranbaxy shows its might! - Views on News from Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Pharma: Ranbaxy shows its might!
Nov 18, 2005

Companies from the Indian pharma sector posted mixed results in the recently concluded September quarter. Barring Ranbaxy, the performance of the other pharma companies was relatively much better. In this article, we take a look at the performance of the pharma sector during the said quarter. We have the included Ranbaxy, Dr.Reddy’s, Cipla, Glaxo and Nicholas Piramal for the purpose of our analysis.

Pharma sector*: A snapshot
(Rs m) Sep-04 Sep-05 Change
Net sales 31,970 32,875 2.8%
Expenditure 24,864 27,714 11.5%
Operating profit (EBIDTA) 7,106 5,161 -27.4%
EBIDTA margin (%) 22.2% 15.7%  
Other income 438 627 43.0%
Interest (net) 228 275 20.7%
Depreciation 1,003 1,105 10.2%
Profit before tax 6,313 4,407 -30.2%
Tax 1,529 587 -61.6%
Extraordinary item 911 2,143 135.2%
Minority interest 8 4 -42.9%
Profit after tax/(loss) 5,687 5,958 4.8%
Net profit margin (%) 17.8% 18.1%  

To Read the Full Story, Subscribe or Sign In

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks